Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); Resubmission Soon: FDA Focus on Full Switch Data, Not CMC
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' on Protalix BioTherapeutics (NYSE: PLX) price target of $8.00.
Canaccord analyst, Ritu Baral, said, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst, Ritu Baral, said, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
